CD 133 Gene Polymorphisms as Predictive Markers for Development of Cancer Pancreas

Abstract

ancreatic cancer is one of the most aggressive human malignancies, it ranks the fourth leading cause of cancer death in the Western world and the 13th commonest cancer The main acquired risk factors for pancreatic cancer are cigarette smoking and, to lesser degree, environmental tobacco smoke, Alcohol, Obesity and physical inactivity, type 1 and type 2 diabetes mellitus and pancreatic cancer, Chronic pancreatitis, and Non-modifiable risk factors as Age, gender and race, Family history and genetic predisposition syndromes Tumor progression is a complex disease process involving various factors, changes of various genes, and the development of multiple stages Cancer stem cells (CSCs) contribute to tumor initiation, metastasis, relapse, and resistance to chemotherapy or radiotherapy, single nucleotide polymorphisms (SNPs) represent the largest proportion of genetic variation in the human genome, and their contribution to cancer susceptibility has been extensively explored, CD133 has been postulated to identify CSC populations in numerous solid tumor types including several forms of cancers and considered an important marker molecule for tumor cells A common type of genetic variation in the genome was single nucleotide polymorphism (SNP) CD133 has multiple SNPs to evaluate the relevance of CD133 SNPs in terms of the risk of Pancreatic cancer (rs2240688, rs1029728, rs3130 and rs2286455)